Key Highlights
- TRexBio raises $84M in Series B led by Delos Capital with new investors Avego BioScience and Agent Capital.
- Funds to advance TRB-061, a TNFR2 agonist, into clinical trials for autoimmune and inflammatory diseases.
- Pipeline expansion to include new candidate TRB-071, leveraging TRexBio’s unique immune-focused platform.
Source: Business Wire
Notable Quotes
- “Regulatory T cells—and TRexBio’s lead program TRB-061 in particular—offer the potential to unlock a new pillar of therapeutic care for autoimmune and inflammatory diseases.” — Dr. Eric Huang, Partner at Delos Capital
- “The funding from this Series B financing enables us to enter the clinic early next year with TRB-061, and to start exploring the breadth of potential therapeutic applications for this novel therapy.” — Johnston Erwin, CEO at TRexBio
SoHC's Take
This $84 million Series B funding is a critical milestone for TRexBio, reinforcing investor confidence in its unique tissue-based immune modulation platform. The lead candidate, TRB-061, demonstrates a promising approach by targeting regulatory T cells (Tregs) to restore immune balance, a departure from conventional immune suppression methods. With Phase 1 trials on the horizon, TRexBio is well-positioned to contribute new therapeutic options for complex autoimmune diseases. The participation of established investors such as Eli Lilly and Johnson & Johnson further underscores the strategic importance of TRexBio’s platform, suggesting that it may yield transformative therapies for unmet patient needs.
